Table 2. HCV–induced liver inflammation and fibrosis is associated with M2 macrophage activation in the liver humans.
| GEO NCBI ID | Clinical Trial Identifier | Infection Status | Age | Liver disease Score | Treatment | Outcome |
|---|---|---|---|---|---|---|
| GSE14323 | LTCDSa | Uninfected | Adult | Normal | NA | NA |
| GSE14323 | NCT00096733 | HCVb | 50.1 (10.9)c | 14.9 (5.7) MELD | NA | End-stage liver disease |
| GSE51699 | NCT01441180 | HCVgt1 | 54 (50, 57)d | 0-1 (80%)3-4 (20%) Knodell-HAI | SOF+RBV (24Weeks) | SVR (90%) Relapsed (10%) |
Notes: ID = Identification; Liver Tissue Cell Distribution System (LTCDS; a = Not Clinical Trial); b = Includes all HCV genotypes; c = Mean (Standard Deviation) (Olthoff, K.M et al.30), d = Median (Interquartile range) (Osinusi, A. et al.31); Model For End-Stage Liver Disease (MELD) and standard deviation (#); Knodell Histology Activity Index (Knodell-HAI) and percentage with score range (%); NA = Non-applicable; SVR = sustained virologic response.